Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fc-gamma receptors (FcγRs) and complement component C1q are distinct but functionally interconnected immune molecules. FcγRs are cell surface receptors expressed primarily on immune cells such as macrophages, neutrophils, and natural killer cells; they recognize the Fc region of IgG antibodies and mediate key effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis. C1q is a soluble pattern recognition molecule that initiates the classical complement pathway by binding to aggregated immunoglobulins (IgG or IgM) or pathogen surfaces, leading to downstream complement activation, opsonization, and lytic attack on targets. The biological activities of therapeutic antibodies depend heavily on their ability to engage FcγRs and/or C1q, and these functions can be differentially engineered to bias immune effector mechanisms. Binding of C1q and FcγRs can also be mutually exclusive, as decoration with C1q may inhibit FcγR engagement on immune complexes, indicating complementary and regulatory roles in immune homeostasis. Both molecules are involved in autoimmunity, infection, tumor immunity, and are targets for immunomodulation through therapeutic antibodies. Note: The query describes an artificial composite target. Scientifically, "Fc-gamma receptor" and "complement component C1q" are distinct and should be treated as separate canonical entries.
Antibody-dependent cellular cytotoxicity (ADCC) via FcγRs: Antibody binding to antigen on target cells, Fc region of antibody binds FcγRs on immune effector cells (e.g., NK cells), leading to cell death. Antibody-dependent cellular phagocytosis (ADCP): FcγRs on phagocytes engage IgG-opsonized particles, resulting in phagocytosis. Complement-dependent cytotoxicity (CDC): C1q binds to Fc of clustered IgG or IgM on cell surfaces, triggers classical complement cascade, and results in cell lysis or opsonization.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fc-gamma receptor and complement component C1q (FcγR and C1q).